Drug Approval | March 27, 2024
FDA approves Merck’s WINREVAIR for treatment of pulmonary arterial hypertension
WINREVAIR is a breakthrough biologic for this rare, progressive disease
WINREVAIR is a breakthrough biologic for this rare, progressive disease
Combination shows consistent benefit across prespecified post-progression outcomes
The pilot plant is focused on scaling up beverage production and will support applications
To accelerate the development of next-generation radioconjugates to treat cancer
Lonza plans to invest approximately CHF 500 million to upgrade the facility
A five-day inspection was concluded successfully with no critical and no major observations raised
Ukrainian marketing approvals for paclitaxel, oxaliplatin and irinotecan mark a significant milestone in the company’s global expansion strategy
Additional capacity broadens Grace’s fine chemical capabilities for API production
Winlevi is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older
New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
Subscribe To Our Newsletter & Stay Updated
